Here’s a bold claim: What if antidepressants start working sooner than we’ve been led to believe? The catch? It all depends on how we measure their effects. A groundbreaking study published in Nature Mental Health on October 30, 2025, challenges the traditional approach of using summary scores to assess antidepressant efficacy. Instead, it suggests that focusing on individual symptoms could reveal much earlier improvements—a game-changer for patients waiting for relief. But here’s where it gets controversial: Could our reliance on broad rating scales have been masking the true potential of these medications all along?
Researchers revisited data from the 2019 PANDA trial, which examined the effects of sertraline—a widely prescribed SSRI—on depression and anxiety symptoms. Their analysis, using a network approach, treated each symptom as a distinct node and mapped its connections to others. The findings? Sertraline showed significant benefits on anxiety and depression symptoms as early as two weeks. However, these improvements were often overshadowed when symptoms were lumped into combined scores, like those from the Patient Health Questionnaire. And this is the part most people miss: SSRIs might directly target specific symptoms, potentially weakening the link between, say, feelings of sadness and guilt—a nuanced effect lost in traditional scoring methods.
While the PANDA study found no overall improvement in depression after six weeks of sertraline use, it uncovered early effects on individual symptoms. These benefits, the authors argue, were likely concealed by side effects on physical symptoms like libido and sleep. This raises a critical question: Are we underestimating antidepressants by not accounting for their symptom-specific impacts?
Atheeshaan Arumuham, from King’s College London, points out that traditional scales blend psychological and physical symptoms, which can muddy the waters. “When these are bundled into a single score, they can mask real improvements in mood and anxiety,” he explains. This study, however, untangles those effects, revealing sertraline’s benefits as highly targeted.
Karen Shuker, president of the College of Mental Health Pharmacy, emphasizes the need for a holistic approach. “We must look beyond total scores and focus on the individual,” she says. Honest conversations about what patients can expect—both good and bad—are crucial for tailored care.
Since October 2025, sertraline and seven other antidepressants have been included in the New Medicines Service (NMS), a move that could significantly impact patient care. Arti Shah, a mental health pharmacist, highlights the role of pharmacists in supporting patients through this journey: “We can provide a listening ear during a challenging time.”
But here’s the bigger question: Should we rethink how we measure antidepressant effectiveness? Could this shift lead to more personalized treatments and better outcomes? Let us know your thoughts in the comments—this debate is far from over.
